icon-craft-studio-shutterstock-com
Icon Craft Studio / Shutterstock.com
6 July 2016Americas

Amgen wins biosimilars case against Apotex at Federal Circuit

The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.

More on this story

Americas
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.

More on this story

Americas
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.